Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort. Filippi M, D'Amico E, Brescia Morra V, Zanetta C, et al. J Neurol 2026;273:302.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Filippi M, D'Amico E, Brescia Morra V, Zanetta C, et al. Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort. J Neurol 2026;273:302.
PMID: 42126632